Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth

Eli Lilly and Co posted better-than-expected quarterly results and raised its full-year revenue forecast on Wednesday, banking on sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs, sending its shares up 5 per cent in premarket trading.